6.
Fleetwood I, Steinberg G
. Arteriovenous malformations. Lancet. 2002; 359(9309):863-73.
DOI: 10.1016/S0140-6736(02)07946-1.
View
7.
Tibarewal P, Rathbone V, Constantinou G, Pearce W, Adil M, Varyova Z
. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development. J Pathol. 2022; 258(4):382-394.
PMC: 9828006.
DOI: 10.1002/path.6009.
View
8.
Pilarski R, Burt R, Kohlman W, Pho L, Shannon K, Swisher E
. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013; 105(21):1607-16.
DOI: 10.1093/jnci/djt277.
View
9.
Andrae J, Gallini R, Betsholtz C
. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22(10):1276-312.
PMC: 2732412.
DOI: 10.1101/gad.1653708.
View
10.
Mulliken J, Glowacki J
. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982; 69(3):412-22.
DOI: 10.1097/00006534-198203000-00002.
View
11.
Kirken R, Wang Y
. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc. 2003; 35(3 Suppl):227S-230S.
DOI: 10.1016/s0041-1345(03)00230-6.
View
12.
Biondi A, Merland J, Reizine D, Aymard A, Hodes J, Lecoz P
. Embolization with particles in thoracic intramedullary arteriovenous malformations: long-term angiographic and clinical results. Radiology. 1990; 177(3):651-8.
DOI: 10.1148/radiology.177.3.2243964.
View
13.
Queisser A, Boon L, Vikkula M
. Etiology and Genetics of Congenital Vascular Lesions. Otolaryngol Clin North Am. 2017; 51(1):41-53.
DOI: 10.1016/j.otc.2017.09.006.
View
14.
Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C
. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994; 8(16):1875-87.
DOI: 10.1101/gad.8.16.1875.
View
15.
Liu A, Mulliken J, Zurakowski D, Fishman S, Greene A
. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg. 2010; 125(4):1185-1194.
DOI: 10.1097/PRS.0b013e3181d18070.
View
16.
Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Herrera-Garcia J, Luque-Valenzuela M, Sanchez-Cano D
. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS). Clin Genet. 2016; 91(1):14-21.
DOI: 10.1111/cge.12832.
View
17.
Caux F, Plauchu H, Chibon F, Faivre L, Fain O, Vabres P
. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet. 2007; 15(7):767-73.
DOI: 10.1038/sj.ejhg.5201823.
View
18.
Marsh D, Kum J, Lunetta K, Bennett M, GORLIN R, Ahmed S
. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999; 8(8):1461-72.
DOI: 10.1093/hmg/8.8.1461.
View
19.
Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C
. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999; 126(14):3047-55.
DOI: 10.1242/dev.126.14.3047.
View
20.
Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A
. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013; 50(4):255-63.
DOI: 10.1136/jmedgenet-2012-101339.
View